Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (Nasdaq: FDMT) reported positive 2-year results from the PRISM Phase 2b trial of intravitreal gene therapy 4D-150 in a broad wet AMD population. The study enrolled 45 patients at two single-dose levels (3E10 and 1E10 vg/eye), with 3E10 vg/eye selected as the dose for 4FRONT Phase 3 trials.
According to 4DMT, best corrected visual acuity and central subfield thickness were consistently maintained through 2 years, with durable reduction in anti-VEGF treatment burden. The overall cohort showed a 78% reduction in supplemental injections (2.7 vs 12.0 projected with aflibercept Q8W), and the recently diagnosed subgroup showed an 87% reduction (1.6 vs 12.0). In combined Phase 1/2a and 2b safety data at the Phase 3 dose (n=71), 2.8% experienced mild, transient intraocular inflammation within 28 weeks, with no new inflammation cases and no specified serious ocular safety events reported with up to more than 4 years of follow-up.
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on July 14, 2026, the board’s compensation committee granted 37,900 Restricted Stock Units (RSUs) to six new non-executive employees. The awards were made under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
4D Molecular Therapeutics (Nasdaq: FDMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in Montreal, Canada, held July 15–18, 2026.
The talk will cover 2-year follow-up data from the PRISM Phase 2b trial of investigational intravitreal gene therapy 4D-150 in a broad neovascular AMD population and will be presented on July 18, 2026, at 2:58–3:01 p.m. ET. The presentation will also be available on the 4DMT website.
4D Molecular Therapeutics (Nasdaq: FDMT) completed global enrollment for its 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD about four months ahead of projections and with over-enrollment (anticipated N>500). Final randomization is expected in Q3 2026, with 52-week topline data in H2 2027. 4FRONT-2 compares intravitreal 4D-150 to aflibercept 2 mg (Q8W), targeting non-inferiority in BCVA and reduced treatment burden. 4FRONT-1, a similar North American Phase 3 trial in treatment-naïve wet AMD, is underway with topline data expected in H1 2027.
4D Molecular Therapeutics (Nasdaq: FDMT) entered a strategic credit facility with Hercules Capital for up to $200 million.
4DMT drew $20 million at closing; further tranches are milestone- and approval-based. Existing cash of $458 million as of March 31, 2026 is expected to fund operations into 2H 2028, excluding this non-dilutive facility.
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on June 9, 2026, its board compensation committee granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
4D Molecular Therapeutics (Nasdaq: FDMT) announced participation in two June 2026 investor conferences. Management will present and hold one-on-one meetings with investors.
The company will present at the Jefferies Global Healthcare Conference on June 3, 2026 at 3:10 p.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 2:00 p.m. ET. Archived webcasts will be available for up to one year on the 4DMT investor website.
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on May 12, 2026, its board compensation committee granted 141,100 Restricted Stock Units (RSUs) to 14 new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
4D Molecular Therapeutics (Nasdaq: FDMT) reported Q1 2026 results and operational updates on May 7, 2026. Key clinical milestones: 4FRONT-1 randomization complete (N=523); 4FRONT-1 topline data expected H1 2027; 4FRONT-2 enrollment expected complete H2 2026 with topline H2 2027. PRISM 2-year data due Q3 2026; SPECTRA 2-year data due H2 2026. Cash, cash equivalents and marketable securities: $458 million as of March 31, 2026, expected to fund operations into H2 2028. Q1 2026 R&D expense: $65.0 million; net loss: $68.8 million.
4D Molecular Therapeutics (Nasdaq: FDMT) announced management will present and hold one-on-one investor meetings at two May 2026 healthcare conferences: BofA Securities 2026 Healthcare Conference on May 13, 2026 at 1:40 p.m. PT, and RBC 2026 Global Healthcare Conference on May 19, 2026 at 2:35 p.m. ET. Archived webcasts will be available for up to one year on the company’s Investors website.